ホーム › リンパ腫 › ノースカロライナ › Durham
Durham、NCにおけるリンパ腫の臨床試験
Durhamとその周辺地域（約30マイル以内）の拠点で、リンパ腫に関する17件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
被験者募集中第2相
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · 10マイル先
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
被験者募集中第2相
- Duke University, Durham
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
被験者募集中第1/2相
- Duke University Medical Center, Durham
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
被験者募集中第1/2相
- UNC School of Medicine, Division of Hematology, Chapel Hill · 10マイル先
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
被験者募集中
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10マイル先
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
被験者募集中第1/2相
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 10マイル先
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
被験者募集中第3相
- Duke Cancer Institute, Durham
DALY II USA/ MB-CART2019.1 for DLBCL
被験者募集中第2相
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
被験者募集中第1相
- Duke University Medical Center, Durham
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
被験者募集中
- North Carolina Basnight Cancer Hospital, Chapel Hill · 10マイル先
Registry of Older Patients With Cancer
被験者募集中観察研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10マイル先
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
被験者募集中第1/2相
- Duke University Medical Center, Duke Cancer Center, Durham
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
被験者募集中第2相
- University of North Carolina, Chapel Hill · 10マイル先
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
被験者募集中
- Duke Cancer Institute, Durham
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
被験者募集中第1相
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · 10マイル先
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
被験者募集中観察研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10マイル先
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
被験者募集中第2相
- Durham VA Medical Center, Durham, NC, Durham
他の都市におけるリンパ腫の試験
- Houston, TX34件の研究
- Boston, MA33件の研究
- New York City, NY33件の研究
- Washington, DC23件の研究
- Baldwin Park, CA21件の研究
- Chicago, IL20件の研究
- St. Louis, MO15件の研究
- Philadelphia, PA15件の研究
- Cleveland, OH14件の研究
- Edison, NJ12件の研究
- Atlanta, GA12件の研究
- Seattle, WA12件の研究
Durhamにおける他の研究
- 乳がん63件の研究
- がん（全種類）58件の研究
- 非小細胞肺癌39件の研究
- 多発性骨髄腫37件の研究
- 転移性癌33件の研究
- 急性骨髄性白血病33件の研究
- 肺がん32件の研究
- 前立腺がん32件の研究
- 大腸癌28件の研究
- 慢性リンパ性白血病27件の研究
- 卵巣がん27件の研究
- 心不全26件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。